Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 129

Sort by

Sort Order Select

Journal Articles

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Blood (2024) 143 (7): 597–603.

https://doi.org/10.1182/blood.2023022083

Published: 2024

Includes: Supplemental data

Journal Articles

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 1461.

https://doi.org/10.1182/blood-2023-186265

Published: 2023

Journal Articles

Mutually-Exclusive Pathways between IKZF1 plus and RAS Mutations and TP53 double-Hit Alterations Lead Relapse in B-Other, Ph-like and Hyperdiploidy Genetic Groups in Adult B-Cell Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 1616.

https://doi.org/10.1182/blood-2023-182163

Published: 2023

Journal Articles

Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 339.

https://doi.org/10.1182/blood-2023-186916

Published: 2023

Journal Articles

Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 646.

https://doi.org/10.1182/blood-2023-186411

Published: 2023

Journal Articles

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Luca Lanino, Somedeb Ball, Jan Philipp Bewersdorf, Monia Marchetti, Giulia Maggioni, Erica Travaglino, Najla H Al Ali, Pierre Fenaux, Uwe Platzbecker, Valeria Santini, Maria Diez-Campelo, Avani M Singh, Akriti Gupta Jain, Luis E. Aguirre, Sara M. Tinsley-Vance, Zaker I. Schwabkey, Onyee Chan, Zhuoer Xie, Andrew M. Brunner, Andrew T. Kuykendall, John M. Bennett, Rena Buckstein, Rafael Bejar, Hetty E. Carraway, Amy E. DeZern, Elizabeth A. Griffiths, Stephanie Halene, Robert Hasserjian, Jeffrey Lancet, Alan F. List, Sanam Loghavi, Olatoyosi Odenike, Eric Padron, Mrinal M. Patnaik, Gail J. Roboz, Maximilian Stahl, Mikkael A. Sekeres, David Peter Steensma, Michael R. Savona, Justin Taylor, Mina Xu, Kendra Sweet, David A Sallman, Stephen D. Nimer, Christopher S. Hourigan, Andrew H. Wei, Elisabetta Sauta, Saverio D'Amico, Gianluca Asti, Gastone Castellani, Uma M. Borate, Guillermo Sanz, Fabio Efficace, Steven D. Gore, Tae Kon Kim, Naval Daver, Guillermo Garcia-Manero, María Rozman, Alberto Orfao, Sa A. Wang, M. Kathy Foucar, Ulrich Germing, Torsten Haferlach, Phillip Scheinberg, Yasushi Miyazaki, Marcelo Iastrebner, Austin Kulasekararaj, Thomas Cluzeau, Shahram Kordasti, Arjan A. van de Loosdrecht, Lionel Ades, Amer M. Zeidan, Rami S. Komrokji, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 998.

https://doi.org/10.1182/blood-2023-186580

Published: 2023

Journal Articles

Kinetics and Biology of Circulating Tumor Cells (CTCs) and Measurable Residual Disease (MRD): Two Dynamic High-Risk Clones in Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 871.

https://doi.org/10.1182/blood-2023-185661

Published: 2023

Journal Articles

Analysis of Single B Cells Reveals a Double Drive of Endocytosis and Transcriptional Downregulation Acting on the CLL B-Cell Receptor In Vivo

Stuart Lanham, Luis Del Rio Fernandez, Joshua Grant, Isla Henderson, Ben Sale, Dean J. Bryant, Lauren Griffith, Alberto Orfao, Freda K. Stevenson, Francesco Forconi

Blood (2023) 142 (Supplement 1): 6508.

https://doi.org/10.1182/blood-2023-188571

Published: 2023

Journal Articles

Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients

Blood (2023) 141 (9): 1036–1046.

https://doi.org/10.1182/blood.2021013489

Published: 2023

Includes: Supplemental data

Journal Articles

High frequency of low-count monoclonal B-cell lymphocytosis in hospitalized COVID-19 patients

Blood (2023) 141 (3): 309–314.

https://doi.org/10.1182/blood.2022017439

Published: 2023

Includes: Supplemental data

Journal Articles

Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

Blood (2022) 140 (Supplement 1): 7166–7167.

https://doi.org/10.1182/blood-2022-168741

Published: 2022

Journal Articles

IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial

Blood (2022) 140 (Supplement 1): 6345–6347.

https://doi.org/10.1182/blood-2022-162159

Published: 2022

Journal Articles

Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow

Blood (2022) 140 (Supplement 1): 2095–2097.

https://doi.org/10.1182/blood-2022-167382

Published: 2022

Journal Articles

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

Daniel A. Arber, Attilio Orazi, Robert P. Hasserjian, Michael J. Borowitz, Katherine R. Calvo, Hans-Michael Kvasnicka, Sa A. Wang, Adam Bagg, Tiziano Barbui, Susan Branford, Carlos E. Bueso-Ramos, Jorge E. Cortes, Paola Dal Cin, Courtney D. DiNardo, Hervé Dombret, Eric J. Duncavage, Benjamin L. Ebert, Elihu H. Estey, Fabio Facchetti, Kathryn Foucar, Naseema Gangat, Umberto Gianelli, Lucy A. Godley, Nicola Gökbuget, Jason Gotlib, Eva Hellström-Lindberg, Gabriela S. Hobbs, Ronald Hoffman, Elias J. Jabbour, Jean-Jacques Kiladjian, Richard A. Larson, Michelle M. Le Beau, Mignon L.-C. Loh, Bob Löwenberg, Elizabeth Macintyre, Luca Malcovati, Charles G. Mullighan, Charlotte Niemeyer, Olatoyosi M. Odenike, Seishi Ogawa, Alberto Orfao, Elli Papaemmanuil, Francesco Passamonti, Kimmo Porkka, Ching-Hon Pui, Jerald P. Radich, Andreas Reiter, Maria Rozman, Martina Rudelius, Michael R. Savona, Charles A. Schiffer, Annette Schmitt-Graeff, Akiko Shimamura, Jorge Sierra, Wendy A. Stock, Richard M. Stone, Martin S. Tallman, Jürgen Thiele, Hwei-Fang Tien, Alexandar Tzankov, Alessandro M. Vannucchi, Paresh Vyas, Andrew H. Wei, Olga K. Weinberg, Agnieszka Wierzbowska, Mario Cazzola, Hartmut Döhner, Ayalew Tefferi

Blood (2022) 140 (11): 1200–1228.

https://doi.org/10.1182/blood.2022015850

Published: 2022

Includes: Supplemental data

Journal Articles

CD34 + CD19 − CD22 + B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

Blood (2022) 140 (1): 38–44.

https://doi.org/10.1182/blood.2021014840

Published: 2022

Includes: Supplemental data

Journal Articles

Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis

Ana Henriques, Javier I. Muñoz-González, Laura Sánchez-Muñoz, Almudena Matito, Lidia Torres-Rivera, María Jara-Acevedo, Carolina Caldas, Andrea Mayado, Alba Pérez-Pons, Andrés C. García-Montero, Iván Álvarez-Twose, Alberto Orfao

Blood (2022) 139 (4): 572–583.

https://doi.org/10.1182/blood.2021012694

Published: 2022

Includes: Supplemental data

Journal Articles

Improved Sézary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sézary syndrome

Safa Najidh, Cornelis P. Tensen, Alita J. van der Sluijs-Gelling, Cristina Teodosio, Davy Cats, Hailiang Mei, Thomas B. Kuipers, Jacoba J. Out-Luijting, Willem H. Zoutman, Thorbald van Hall, Alberto Orfao, Julia Almeida, Jacques J. M. van Dongen, Maarten H. Vermeer

Blood (2021) 138 (24): 2539–2554.

https://doi.org/10.1182/blood.2021012286

Published: 2021

Includes: Supplemental data

Journal Articles

Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints

Blood (2021) 138 (Supplement 1): 76.

https://doi.org/10.1182/blood-2021-146535

Published: 2021

Journal Articles

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Blood (2021) 138 (Supplement 1): 541.

https://doi.org/10.1182/blood-2021-150092

Published: 2021

Journal Articles

Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials

Blood (2021) 138 (Supplement 1): 3486.

https://doi.org/10.1182/blood-2021-148263

Published: 2021

NARROW

Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

Role of Allogeneic Stem Cell Transplantation in Preventing Relapse in Adult BCR::ABL1-like Acute Lymphoblastic Leukemia

Mutually-Exclusive Pathways between IKZF1 plus and RAS Mutations and TP53 double-Hit Alterations Lead Relapse in B-Other, Ph-like and Hyperdiploidy Genetic Groups in Adult B-Cell Acute Lymphoblastic Leukemia

Minimally Invasive Assessment of Measurable Residual Disease (MRD) in Multiple Myeloma (MM)

Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)

Data-Driven Harmonization of 2022 Who and ICC Classifications of Myelodysplastic Syndromes/Neoplasms (MDS): A Study By the International Consortium for MDS (icMDS)

Kinetics and Biology of Circulating Tumor Cells (CTCs) and Measurable Residual Disease (MRD): Two Dynamic High-Risk Clones in Multiple Myeloma (MM)

Analysis of Single B Cells Reveals a Double Drive of Endocytosis and Transcriptional Downregulation Acting on the CLL B-Cell Receptor In Vivo

Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients

High frequency of low-count monoclonal B-cell lymphocytosis in hospitalized COVID-19 patients

Determining Hemodilution in Diagnostic Bone Marrow Samples in Multiple Myeloma and Its Precursors By Next-Generation Flow Cytometry: Data from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study

IKZF1 Deletions Are Markers of Treatment Resistance in Adult Ph-Negative B-Cell Acute Lymphoblastic Leukemia Patients Treated within the Ongoing Risk-Adapted Pethema LAL19 Trial

Ultra-Sensitive Assessment of Measurable Residual Disease (MRD) in Peripheral Blood (PB) of Multiple Myeloma (MM) Patients Using Bloodflow

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data

CD34 + CD19 − CD22 + B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies

Frequency and prognostic impact of blood-circulating tumor mast cells in mastocytosis

Improved Sézary cell detection and novel insights into immunophenotypic and molecular heterogeneity in Sézary syndrome

Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints

Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies

Genomic Data Improves Prognostic Stratification in Adult T-Cell Acute Lymphoblastic Leukemia Patients Enrolled in Measurable Residual Disease-Oriented Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only